Brookline Capital Markets Forecasts CRDL FY2026 Earnings

Cardiol Therapeutics Inc. (NASDAQ:CRDL – Free Report) – Equities researchers at Brookline Capital Markets issued their FY2026 earnings estimates for Cardiol Therapeutics in a research note issued to investors on Monday, November 16th. Brookline Capital Markets analyst F. Ahmed expects that the company will earn ($0.25) per share for the year. The consensus estimate for Cardiol Therapeutics’ current full-year earnings is ($0.20) per share. Brookline Capital Markets also issued estimates for Cardiol Therapeutics’ Q4 2026 earnings at ($0.07) EPS.

Cardiol Therapeutics (NASDAQ:CRDL – Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02).

A number of other equities analysts have also commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Cardiol Therapeutics in a report on Monday, September 21st. B. Riley Financial started coverage on shares of Cardiol Therapeutics in a report on Wednesday, August 26th. They set a “buy” rating and a $11.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and set a $9.00 price objective on shares of Cardiol Therapeutics in a report on Wednesday, September 23rd. Canaccord Genuity Group upped their target price on shares of Cardiol Therapeutics from $8.00 to $10.00 and gave the stock a “buy” rating in a research report on Monday, August 17th. Finally, Wall Street Zen cut Cardiol Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 14th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $10.00.

View Our Latest Research Report on Cardiol Therapeutics

Cardiol Therapeutics Price Performance

CRDL stock opened at $0.86 on Thursday. Cardiol Therapeutics has a one year low of $0.84 and a one year high of $2.34. The firm has a 50 day simple moving average of $1.30 and a two-hundred day simple moving average of $1.30.

Institutional Investors Weigh In On Cardiol Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Parallel Advisors LLC bought a new position in shares of Cardiol Therapeutics during the third quarter valued at about $32,000. Royal Bank of Canada boosted its holdings in shares of Cardiol Therapeutics by 62.3% during the first quarter. Royal Bank of Canada now owns 21,648 shares of the company’s stock worth $29,000 after purchasing an additional 8,306 shares during the period. Virtu Financial LLC purchased a new stake in shares of Cardiol Therapeutics during the third quarter worth about $42,000. Concurrent Investment Advisors LLC purchased a new stake in shares of Cardiol Therapeutics during the second quarter worth about $27,000. Finally, Cibc World Market Inc. bought a new stake in shares of Cardiol Therapeutics in the third quarter worth about $55,000. Institutional investors own 12.49% of the company’s stock.

Cardiol Therapeutics Company Profile

(Get Free Report)

Cardiol Therapeutics is a Canadian biotechnology company developing therapies for inflammatory heart disease and other cardiovascular conditions. Its research focuses on treatments intended to address inflammation and related damage to the heart. The company’s lead candidate, CardiolRx, is a pharmaceutical-grade cannabidiol formulation under clinical investigation for conditions including myocarditis and pericarditis. Cardiol also has CRD-38, an investigational candidate being studied for potential use in heart failure.

Recommended Stories

Earnings History and Estimates for Cardiol Therapeutics (NASDAQ:CRDL)

Receive News & Ratings for Cardiol Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiol Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.